FRANKLIN, Tenn., May 8, 2024 – Azra AI, a healthtech leader harnessing artificial intelligence (AI) and workflow automation to accelerate the identification and treatment of cancer, is thrilled to announce the appointment of John Marshall as its new Chief Executive Officer. Marshall will succeed Chris Cashwell, who will continue to support Azra as an advisor. With more than 25 years of experience in technology and healthcare, Marshall brings deep expertise in market-leading strategies and first-to-market technologies to drive Azra AI’s growth in response to rising market demand.
Marshall, a visionary executive and accomplished sales leader, has a remarkable history of expanding domestic and global market channels through dynamic sales strategies, focused P&L discipline, driving product innovation, and unique team-building techniques. His leadership has guided several companies to the forefront of medical imaging, data management, and health IT.
"Given the increasing demand for AI-driven healthcare solutions, John Marshall is the ideal leader to propel Azra AI to new heights. His extensive expertise in both technology and healthcare, along with a proven track record of leadership, makes him uniquely qualified to steer the company through this exciting growth phase," said Abinav Sankar, Chairman of the Board at Azra AI and partner at Sopris Capital. "I also want to express my gratitude to Chris Cashwell for his exceptional work in positioning Azra AI as a healthtech leader and setting the stage for a promising future."
Marshall has a proven track record of bringing first-of-its-kind technologies to market, impacting healthcare systems, IDNs, diagnostic reading groups, pharma, and contract research organizations worldwide. His sales and executive leadership abilities include developing strategic sales and product plans, as well as recruiting dynamic teams that lead markets with best-of-breed partners and channel management.
Prior to joining Azra AI, John Marshall served as Chief Operating Officer at Enlitic, Inc., where he guided the company to a successful IPO in December 2023, starting from zero revenue and building global sales and marketing teams. As Global VP of Sales at Client Outlook, he was able to globally commercialize their technology to the point of an all-cash acquisition by Mach7 Technologies in 2020. Marshall’s leadership as Global VP of Sales at Calgary Scientific turned a start-up with no revenue or sales teams, into a multimillion-dollar global software provider.
"I'm excited to join the talented team at Azra AI and contribute to a mission that aligns so closely with my passion for leveraging technology to make a real difference in healthcare. Automatically identifying, classifying, and abstracting cancer diagnoses and incidental findings from pathology and radiology reports makes an enormously positive impact not only for oncology operations, but for patients and their ability to know about their cancer earlier, thus giving them a chance to survive and beat cancer. Together, we'll push the boundaries of innovation at Azra, ensuring that our solutions continue to empower hospitals and cancer centers to provide the best care possible while enhancing operational efficiency, deep clinical outcomes, and capitalizing on real ROI. I could not be more excited and thankful for this opportunity," said Marshall.
Azra AI’s enterprise SaaS platform revolutionizes oncology care with advanced AI-driven automation that transforms workflows, improves cancer navigation, and empowers healthcare providers to act swiftly on positive cancer diagnoses and suspicious incidental findings. With John Marshall's strategic leadership and focus on expanding the platform's innovative capabilities, Azra AI will continue to drive impactful improvements in operational efficiency, patient care, and service line growth across the healthcare industry.
About Azra AI
Azra AI is a healthtech firm that leverages advanced AI and machine learning to automate oncology workflows. Its proven SaaS enterprise platform is used by more than 200 hospitals and cancer centers across the country to identify positive cancer diagnoses and incidental findings in real-time, classify by primary site, and route those patients to cancer navigators and other staff to immediately start the cancer care journey. The results include faster time to treatment, increased navigator time with patients, and better oncology patient retention. Additionally, the solution delivers dramatic operational and financial gains through intelligent automation.
